Filing Analysis
Modular Medical, Inc. entered into a placement agency agreement for a registered direct offering of 750,000 shares of common stock. The offering is expected to yield approximately $3.375 million in gross proceeds to the company.
Red Flags
- Shareholder dilution resulting from the issuance of 750,000 new shares.
- The relatively small size of the raise ($3.375M) may suggest immediate liquidity needs for a micro-cap company.
Key Facts
- The offering involves 750,000 shares of common stock at a price resulting in $3.375 million gross proceeds.
- Maxim Group LLC is acting as the placement agent, receiving a 7% cash fee and up to $75,000 in expense reimbursement.
- Directors and executive officers are subject to a 90-day lock-up agreement.
- The company is prohibited from issuing additional securities for 45 days following the closing date of April 21, 2026.
- The offering was conducted under an existing Form S-3 registration statement (No. 333-287313).
Modular Medical, Inc. announced that it has regained compliance with Nasdaq's minimum bid price requirement as of April 15, 2026. The company received a formal notification from the Nasdaq Listing Qualifications Department confirming it met the standards of Rule 5550(a)(2).
Red Flags
- The company was previously non-compliant, indicating the stock had been trading below $1.00 for a sustained period
Key Facts
- Notification of compliance received on April 15, 2026
- Compliance relates to Nasdaq Listing Rule 5550(a)(2) regarding the $1.00 minimum bid price
- The company issued a corresponding press release on April 16, 2026
- The matter is now considered closed by Nasdaq
Modular Medical, Inc. implemented a 1-for-30 reverse stock split of its common stock effective March 31, 2026. The split was previously approved by the board and shareholders to consolidate shares and likely maintain compliance with Nasdaq listing requirements.
Red Flags
- Large reverse split ratio (1-for-30) indicates significant share price erosion prior to the event.
- Authorized shares were not reduced in proportion to the split, which creates massive 'headroom' for future equity dilution without further shareholder votes.
Key Facts
- Reverse stock split ratio of 1-for-30 effective as of 5:30 a.m. ET on March 31, 2026.
- The number of authorized shares of Common Stock and the par value ($0.001) remain unchanged.
- Common stock began trading on a post-split basis on March 31, 2026, under a new CUSIP (60785L306).
- No fractional shares will be issued; holders will receive cash in lieu of fractional shares.
- Outstanding equity awards and warrants will be adjusted (shares divided by 30, exercise price multiplied by 30).
Modular Medical, Inc. implemented a significant workforce reduction on March 12, 2026, laying off 20 employees to reduce cash burn. This reduction represents approximately 29% of the company's total workforce and is intended to prioritize projects with higher ROI.
Red Flags
- Substantial workforce reduction (29%) indicates significant liquidity or cash runway pressure.
- Explicit mention of the need to reduce 'cash burn' suggests the company may be facing a capital crunch.
- A reduction of this scale in a medical technology company may impact R&D timelines or commercialization efforts.
Key Facts
- Layoff of 20 positions, representing 29% of the workforce, occurred on March 12, 2026.
- The reduction is expected to decrease annual operating expenses by approximately $3.4 million.
- Estimated non-recurring charges for severance are between $0.1 million and $0.2 million.
- The majority of restructuring charges are expected to be incurred by the quarter ending June 30, 2026.
- The stated purpose is to reduce operating expense and cash burn.
Modular Medical, Inc. closed a $12 million best-efforts public offering of common stock and warrants on March 4, 2026. The offering is highly dilutive, involving the issuance of approximately 68 million shares (including pre-funded warrants) and an equivalent number of common warrants at a combined price of $0.1762 per unit.
Red Flags
- Extreme dilution risk: The issuance of 68 million common warrants represents 100% warrant coverage relative to the shares/pre-funded warrants issued.
- Low nominal share price: The offering price of $0.1762 suggests the company is operating in penny stock territory, which often precedes volatility or potential delisting risks.
- Best-efforts offering: Unlike a firm commitment underwriting, a best-efforts deal may indicate lower institutional demand.
Key Facts
- The company raised approximately $12 million in gross proceeds before fees and expenses.
- The offering consisted of 62,098,000 shares of common stock and 6,000,000 pre-funded warrants.
- Each share or pre-funded warrant was accompanied by a common warrant, totaling 68,098,000 common warrants with an exercise price of $0.1762.
- The combined public offering price was $0.1762 per share and accompanying warrant.
- Maxim Group LLC acted as the placement agent, receiving a 7% cash fee and $100,000 in expense reimbursements.
- Directors and executive officers are subject to a 90-day lock-up period.
Modular Medical, Inc. entered into a $350,000 secured revolving credit facility with its CEO, James E. Besser, on February 23, 2026. The facility is extremely short-term, maturing on March 25, 2026, and is secured by all of the company's assets and intellectual property.
Red Flags
- Related-party transaction involving the CEO as the primary lender.
- Extremely short-term maturity (30 days) suggests an immediate liquidity crisis.
- High cost of capital: 12% flat interest for a 30-day period is equivalent to an extremely high annual percentage rate.
- The Company has pledged its entire asset base and intellectual property for a relatively small $350,000 facility.
- The terms indicate the company is likely in desperate need of bridge financing to reach a larger equity raise.
Key Facts
- The lender is James E. Besser, the Company's CEO.
- The credit facility provides up to $350,000 in revolving credit.
- The maturity date is March 25, 2026, approximately one month from the agreement date.
- Interest is set at a flat rate of 12% on each drawdown, regardless of the duration the funds are held.
- The loan is secured by all assets and intellectual property of the Company.
- Repayment is required earlier than maturity if the Company receives proceeds exceeding $2,000,000 from equity financings.